A study conducted at The Department of Urology, Yokosuka Kyosai Hospital, Japan, evaluated the efficacy and safety of using a low-dose chemotherapy combination of docetaxel, estramustine and dexamethasone in men with castrate resistant prostate cancer (CRPC). The study enrolled sixty-nine with CRPC. Docetaxel dosage was downed to 25 mg/m2 on days 1 and 8 every [...]
At Columbia University, New York City, Dr. Aaron Katz, in an online publication of Integrative Cancer Therapies reported positive effects on both androgen dependent (AD) and androgen independent (AI) prostate cancer of Modified Citrus Pectin (MCP) on both human and mouse prostate cancer cell lines (in the petrie dish). Dr. Kata, the lead researcher, reported [...]
In June of 2009 a team at UCSF Department of Urology announced a new prostate cancer risk assessment test that they claim can provide men and their doctors a better way of gauging long-term risks and pinpointing high risk cases of prostate cancer. The test, as indicated by the researchers, proved accurate in predicting bone [...]
There remain for many people questions about Provenge. The most common question I hear is about the financial cost of the treatment for what has been described as “only 4 months of life extension for $93,000, is it worth it?” Well, the answer is a clear yes! […]
A study by Yu et al., of men with a rising PSA after failed radical prostatectomy or radiation therapy who were placed on intermittent androgen deprivation therapy (IADT) indicated that the length of their first “off cycle” correlates with their expected time to developing castrate resistant prostate cancer (CRPC) and to their prostate cancer-specific mortality. [...]
We know that approximately one-third of all men who elect to have a radical prostatectomy for localized prostate cancer will ultimately experience a biochemical (PSA) recurrence. Researchers at the Department of Urology, Loyola University Medical Center, Maywood, IL, report on their long-term outcomes of salvage radiotherapy (SRT). […]
The Food and Drug Administration (FDA) has announced that it is looking into reports that Glaxo Smith Kline’s prostate drug Avodart and Merck & Co’s prostate drug Proscar may be contributing to an increase of male breast cancers. […]
Watson Pharmaceuticals announced that it has received approval from the FDA for its new six-month intramuscular formulation, Trelstar, a (triptorelin pamoate for injectable suspension) 22.5 mg. Trelstar 22.5 mg is a gonadotropin releasing hormone (GnRH) agonist used for the palliative treatment of advanced prostate cancer. […]
Many of us once considered drinking coffee nothing but a bad habit, but now it looks as if drinking coffee is actually a good thing for us. Researchers are finding more and more benefits from drinking coffee, from preventing cancer to fighting fatigue. […]
Hormone therapy (ADT), using luteinizing hormone releasing hormone (LHRH) agonists or gonadatropin releasing hormone or GnRH agonists (Lupron, Zoladex, Trelstar, Viadur, Vantas, Eligard and Synarel ) have been known to have many side effects, some severe and potentially life threatening. Many of us believe that ADT is associated with cardiovascular disease and diabetes along with [...]
